Bayraktar, Soley <br/><br/>
Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy.  [electronic resource] 

 -  Medical oncology (Northwood, London, England)  Oct 2014 
 - 163 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1559-131X 
<br/><br/><label>Standard No.: </label>10.1007/s12032-014-0163-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Biomarkers, Tumor--genetics<br/>Breast Neoplasms--drug therapy<br/>Capecitabine<br/>Deoxycytidine--analogs & derivatives<br/>Docetaxel<br/>Female<br/>Fluorouracil--analogs & derivatives<br/>Gene Expression Profiling--methods<br/>Humans<br/>Middle Aged<br/>Mutation<br/>Neoadjuvant Therapy<br/>Polymerase Chain Reaction<br/>Prospective Studies<br/>Receptor, ErbB-2--metabolism<br/>Receptors, Estrogen--metabolism<br/>Receptors, Progesterone--metabolism<br/>Retrospective Studies<br/>Taxoids--therapeutic use<br/>Trastuzumab<br/>Treatment Outcome<br/>Tumor Suppressor Protein p53--genetics